Latest News Archive

Please select Category, Year, and then Month to display items

Kovsie student Moeketsi Ngesemane making his mark through Sesotho music

15 December 2021 | Story Nondsindiso Qwabe | Photo Supplied

Bachelor of Education third-year student, Moeketsi ‘Escalator’ Ngesemane.

By day he is a third-year Bachelor of Education student on the Qwaqwa Campus, but this young man is a Sesotho music maestro with a deep-rooted passion for traditional music and a diligent devotion to unearthing new talent and connecting more people to the cultural artistry that Sesotho music has to offer.

Moeketsi Ngesemane, better known as ‘Escalator’ in the world of music, is only 22 years old, but he has already released one solo album and featured in two more, leads a group of more than 80 traditional singers and dancers, and is responsible for a string of groups around Qwaqwa. He has made strides far beyond his age, and Ngesemane says he is only getting started. He was also instrumental in coordinating the Qwaqwa traditional groups that performed during this year’s Multilingual Mokete festival, where he also featured.

Born and bred in Qwaqwa, Ngesemane pins his love for traditional music as something that was cultivated in his childhood while singing traditional songs with his mother and brother. “My mother is a traditional healer, so Sesotho music was a big part of my upbringing. As I grew older, my brother and I would perform in town and people would give us money. I have not looked back since.”

He cemented himself as an artist and artist manager in his first year in 2009. The name ‘Escalator’ came about in an uncanny way, as he fondly recalls. “I had a friend who was afraid of escalators when he first saw it – but I wasn’t, so he named me ‘Escalator’. I hated the name until I personalised the meaning behind it. It is able to take people from one point to another and from one level to another, which is something I am passionate about doing through traditional music, so the name was fitting.”

He captivated the minds and hearts of both young and old people who want to be under his leadership, and he grooms young people as young as ten, who will also thrive and take traditional praise singing and dancing to greater heights. This, he says, helps him alleviate some responsibilities so that he can focus on his schoolwork.

Celebrating the Sesotho culture through music

Word about his music skill often spreads quickly. “Even when I am on teaching practicals at different schools, once learners find out what I do, they ask to join my group and I can’t say no. Their ages range from 7 to 21, and I know that my group will have more than 100 members before the year ends,” he said.

He often puts together music shows with his group around Qwaqwa. This, he says, he does to promote Sesotho music and art.

Ngesemane has been selected to represent the Basotho Kingdom at the Indoni Mr and Miss Cultural South Africa – an indigenous event focused on promoting South Africa’s diverse cultural heritage, taking place at the Durban ICC on 17 December. He describes this as a dream come true.

“It’s a great honour to be representing the Basotho culture. I have discovered that young people, especially, have neglected their cultural roots and often look down on traditional music and regalia. I’ve made it my personal aim to promote and uphold the Sesotho culture through praise singing and dancing.”

You can vote for Ngesemane by SMS’ing ‘Indoni Mr Sotho’ to 33616.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept